KPIs & Operating Metrics(New)
Assets By SegmentBreakdown Of AssetsCapital Expenditure By SegmentCost Of Goods And Services SoldDeferred IncomeDepreciation And Amortization By SegmentEmployee StatisticsGross Margin %Gross Margin By Segment %Gross Margin By Segment Annual %Gross ProfitGross Profit By SegmentGross Profit By Segment AnnualIncome Before Income TaxLong Lived Assets By GeographyNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Operating Lease LiabilitiesOperating Margin By Segment %Operating Profit By SegmentOpex As A % Of Total Revenue %OPEX SegregationProperty, Plant And Equipment, Net BreakdownRevenue By Country AnnualRevenue By Country Annual %Revenue By GeographyRevenue By Geography %Revenue By Geography AnnualRevenue By Geography Annual %Revenue By Market GroupRevenue By Market Group %Revenue By Market Group AnnualRevenue By Market Group Annual %Revenue By Product CategoryRevenue By Product Category %Revenue By Product Category AnnualRevenue By Product Category Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Gross Profit (2016 - 2025)

West Pharmaceutical Services' Gross Profit history spans 17 years, with the latest figure at $303.9 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 11.07% year-over-year to $303.9 million; the TTM value through Dec 2025 reached $1.1 billion, up 10.57%, while the annual FY2025 figure was $1.1 billion, 10.57% up from the prior year.
  • Gross Profit for Q4 2025 was $303.9 million at West Pharmaceutical Services, up from $294.3 million in the prior quarter.
  • Across five years, Gross Profit topped out at $321.5 million in Q2 2022 and bottomed at $230.0 million in Q2 2024.
  • The 5-year median for Gross Profit is $276.0 million (2023), against an average of $277.2 million.
  • The largest annual shift saw Gross Profit soared 62.81% in 2021 before it decreased 21.07% in 2024.
  • A 5-year view of Gross Profit shows it stood at $300.6 million in 2021, then decreased by 12.81% to $262.1 million in 2022, then rose by 6.14% to $278.2 million in 2023, then decreased by 1.65% to $273.6 million in 2024, then increased by 11.07% to $303.9 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Gross Profit are $303.9 million (Q4 2025), $294.3 million (Q3 2025), and $273.9 million (Q2 2025).